Crossin K L, Carney D H
Cell. 1981 Jan;23(1):61-71. doi: 10.1016/0092-8674(81)90270-1.
Microtubule disrupting drugs initiated DNA synthesis in serum-free cultures of nonproliferating fibroblast-like cells. The addition of colchicine to chick, mouse and human fibroblasts in serum-free medium stimulated thymidine incorporation at least twofold, with a half-maximal concentration of 1 X 10(-7) M. This stimulation represented up to 75% of the maximal stimulation by thrombin and was paralleled by an increase in the percentage of labeled nuclei. Other microtubule disrupting drugs showed similar stimulation, whereas lumicolchicine had no effect. Indirect immunofluorescent staining of tubulin showed a correlation between microtubule depolymerization and initiation of DNA synthesis by these drugs. A 2 hr treatment with 10(-6) M colchicine caused complete disruption of the microtubular network and stimulated thymidine incorporation (measured 28 hr later) to an even greater extent than continuous colchicine exposure. A similar 2 hr exposure to 10(-6) M colcemid also stimulated thymidine incorporation and led to a 50% increase in cell number. Taxol, a drug which stabilizes cytoplasmic microtubules, blocks initiation of DNA synthesis by colchicine, indicating that microtubule depolymerization is necessary for this initiation. To determine if microtubule depolymerization is involved in stimulation of DNA synthesis by other growth factors, highly purified human thrombin was added to cells with or without colchicine. In no case did colchicine plus thrombin increase DNA synthesis above that of the maximal stimulation by thrombin alone. Furthermore, pretreatment of cultures with taxol (5 micrograms/ml) inhibited approximately 30% of the stimulation of thymidine incorporation by thrombin. Together, these studies demonstrate that microtubule depolymerization is sufficient to initiate both DNA synthesis and events leading to cell division and suggest that microtubule depolymerization may be a required step in initiation of cell proliferation by growth factors such as highly purified human thrombin.
微管破坏药物可在无血清培养的非增殖性成纤维细胞样细胞中启动DNA合成。在无血清培养基中,向鸡、小鼠和人成纤维细胞添加秋水仙碱可刺激胸苷掺入至少两倍,半数最大浓度为1×10⁻⁷M。这种刺激高达凝血酶最大刺激的75%,同时标记细胞核的百分比也增加。其他微管破坏药物也显示出类似的刺激作用,而光秋水仙碱则无作用。微管蛋白的间接免疫荧光染色显示微管解聚与这些药物引发的DNA合成之间存在相关性。用10⁻⁶M秋水仙碱处理2小时会导致微管网络完全破坏,并比持续暴露于秋水仙碱更能刺激胸苷掺入(28小时后测量)。类似地,暴露于10⁻⁶M秋水仙酰胺2小时也刺激了胸苷掺入,并导致细胞数量增加50%。紫杉醇是一种可稳定细胞质微管的药物,它可阻断秋水仙碱引发的DNA合成,表明微管解聚是这种引发所必需的。为了确定微管解聚是否参与其他生长因子对DNA合成的刺激,将高度纯化的人凝血酶添加到有或没有秋水仙碱的细胞中。在任何情况下,秋水仙碱加凝血酶都不会使DNA合成超过单独凝血酶的最大刺激。此外,用紫杉醇(5微克/毫升)预处理培养物可抑制凝血酶对胸苷掺入刺激的约30%。总之,这些研究表明微管解聚足以启动DNA合成和导致细胞分裂的事件,并表明微管解聚可能是生长因子(如高度纯化的人凝血酶)启动细胞增殖的必要步骤。